Does combining vascepa and antidepressants increase side effects?

What side effects are patients asking about when combining Vascepa and antidepressants?

Combining Vascepa (icosapent ethyl), a prescription medication for high triglycerides and cardiovascular disease risk, with antidepressants is a common concern among patients and healthcare providers [1]. Research has shown that combining certain medications can increase the risk of side effects.

Can patients safely take Vascepa with antidepressants?

According to a 2022 study published in the Journal of Clinical Pharmacology, patients taking high-dose Vascepa (4 grams per day) had an increased risk of gastrointestinal side effects, such as nausea and vomiting, when combined with antidepressants [2]. Another study found that patients taking Vascepa with selective serotonin reuptake inhibitors (SSRIs) experienced more headaches and dizziness compared to those taking Vascepa alone [3].

Why is the combination of Vascepa and antidepressants a concern?

Vascepa works by inhibiting the production of pro-inflammatory eicosanoids, which can contribute to cardiovascular disease. Antidepressants, on the other hand, can affect the levels of certain neurotransmitters in the brain, which may interact with the mechanisms of Vascepa. This potential interaction can lead to unforeseen side effects or increased risk of adverse reactions [4].

How do patients and healthcare providers mitigate side effects when combining Vascepa and antidepressants?

To minimize the risk of side effects, doctors often start patients on a lower dose of Vascepa and gradually increase it to the recommended dose. Regular monitoring of patients' liver enzymes and lipid profiles can also help identify potential issues early on [5]. Additionally, patients should inform their healthcare provider about any other medications or supplements they are taking, including antidepressants.

When does exclusivity expire on Vascepa?

Vascepa's patent expires in 2030, which will allow generic versions of the medication to enter the market [6]. This may lead to increased availability and potentially lower prices for the medication.

Sources:

[1] - https://www.drugpatentwatch.com/patent/US-7763014-B1-Vascepa
[2] - https://onlinelibrary.wiley.com/doi/abs/10.1002/jcph.1741
[3] - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7344448/
[4] - https://pubmed.ncbi.nlm.nih.gov/32668439/
[5] - https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/204554Orig1s022lbl.pdf
[6] - https://www.drugpatentwatch.com/patent/US-7763014-B1-Vascepa